Skip to main content
Clinical Trials/NL-OMON43996
NL-OMON43996
Completed
Not Applicable

Tack Optimized Balloon Angioplasty Study for the Superficial Femoral and Proximal Popliteal Arteries Using the Tack Endovascular System. (TOBA II) - The TOBA II study

Intact Vascular0 sites15 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
atherosclerosis
Sponsor
Intact Vascular
Enrollment
15
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
Intact Vascular

Eligibility Criteria

Inclusion Criteria

  • CLINICAL INCLUSION CRITERIA;1\. \* 18 years
  • 3\. Target limb requires no additional treatment aside from the target lesion and ipsilateral iliac artery
  • 6\. Rutherford Classification 2, 3 or 4
  • 8\. Eligible for standard surgical repair, if necessary
  • 9\. Subject is ambulatory (assistive devices such as a cane or walker is acceptable);ANGIOGRAPHIC INCLUSION CRITERIA;1\. Reference vessel diameter is between 2\.5 mm and 6\.0 mm, inclusive (by visual estimate)
  • 2\. Ability to cross a guidewire (antegrade) through target lesion
  • 3\. Has a de novo or non\-stented restenotic target lesion indicated for PTA treatment with a
  • standard or FDA\-approved Lutonix drug\-coated balloon catheter that meets the following
  • criteria below:
  • a. 70% to 99% stenosis with a total lesion length of \*20mm and \*150mm in length (by visual estimate) or

Exclusion Criteria

  • CLINICAL EXCLUSION CRITERIA;1\. Rutherford Classification 0, 1, 5 or 6
  • 2\. Is pregnant or refuses to use contraception through the duration of the study
  • 3\. Previous infrainguinal bypass graft in the target limb
  • 8\. Prior coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI) procedure within 30 days prior to the index procedure or planned CABG/PCI within 30 days after the index procedure
  • 9\. Any other previous or planned surgical or endovascular procedure (not including
  • diagnostic procedures) within 14 days prior to or 30 days post index procedure
  • 10\. Planned atherectomy, cryoplasty, stenting or any other treatment (with the exception of a crossing device) of the target lesion other than PTA during the index procedure
  • 16\. Requires treatment of tibial or outflow vessels at the index procedure, which include the P2 and P3 segments of the popliteal artery and the tibioperoneal vessels.
  • 18\. Participating in another ongoing investigational clinical trial that has not completed its primary endpoint;ANGIOGRAPHIC EXCLUSION CRITERIA:;1\. Retrograde access through target limb
  • 2\. Acute vessel occlusion or acute or sub\-acute thrombosis in target lesion

Outcomes

Primary Outcomes

Not specified

Similar Trials